Our website uses cookies to improve your on-site experience. By using the website, cookies are being used as described in our Policy Document
Warning: To log in you will need to enable cookies and reload the page (Policy Document)
My ePortfolio Register   

Precision medicine in ALK-positive NSCLC: Results from the BFAST trial

Please rate this video

Please complete at least one question.

  1. The information in this video was of interest to me Disagree Agree
  2. The information in this video is likely to improve my clinical practice or research Disagree Agree
  3. I would recommend this video to my colleagues Disagree Agree
Submit
Thanks for rating
There has been a problem, please refresh and try again.
Published: 03.10.19
Views: 2684
Rating:

Prof Solange Peters and Prof Tony Mok

Prof Solange Peters (Centre Hospitalier Universitaire Vaudois, Lausanne, Switzerland) and Prof Tony Mok (Chinese University of Hong Kong, Hong Kong) discuss the latest developments presented at ESMO 2019 in ALK-positive non-small-cell lung cancer (NSCLC), including updates in precision medicine.

Prof Mok outlines the current landscape of ALK-positive NSCLC and discusses the BFAST study, which uses a blood-based assay to screen patients to detect patients with ALK fusions.

The experts discuss the clinical utility of this screening tool, which may be beneficial to patients with insufficient tissue for testing and may help oncologists understand the mechanisms of resistance to alectinib in these patients.

Prof Peters concludes by discussing the latest results from the CheckMate 227 trial and the role of ipilimumab plus nivolumab (I-O) combination in ALK-positive patients.

This programme has been supported by an unrestricted educational grant from Roche.

Related videos

follow us

Biosimilar Medicines Core Principles and Communication


Founding partners

European Cancer Organisation European Institute of Oncology

Founding Charities

Foundazione Umberto Veronesi Fondazione IEO Swiss Bridge

Published by

ecancer Global Foundation